Low-risk (Gleason 6)
Slow-growing, organ-confined. Often suitable for active surveillance — watching closely, treating only if anything changes.
Prostate Cancer Treatment in Hyderabad
Prostate cancer is the textbook example of "more than one right answer" in oncology. For low-risk disease, active surveillance and definitive treatment are both medically defensible. Dr. Madhav Danthala provides treatment planning, hormonal therapy, chemotherapy, and second opinions at Omega Hospitals, Gachibowli, and Peoples Polyclinic, Manikonda.
Risk Categories
Prostate cancer ranges from indolent disease that may never cause harm to aggressive cancers requiring prompt treatment.
Intermediate-risk (Gleason 7)
Treatment usually involves surgery or radiation, sometimes combined with short-course hormonal therapy.
High-risk (Gleason 8-10)
Requires prompt definitive treatment with surgery and/or radiation, plus longer-term hormonal therapy.
When to See a Doctor
Early prostate cancer often has no symptoms. Symptomatic presentation usually means more advanced disease.
Urinary symptoms
Frequent urination at night, weak stream, difficulty starting or stopping urine flow, urgency.
Blood in urine or semen
Any visible blood in urine or semen warrants evaluation.
Persistent pelvic pain
Pelvic, hip, or lower-back pain that does not resolve.
Family history concerns
First-degree relative with prostate cancer (or BRCA mutation) — discuss earlier PSA screening with your doctor.
Dr. Danthala's Approach
Prostate cancer is the cancer where shared decision-making matters most.
Risk-led planning
Treatment intensity should match disease aggressiveness. Over-treatment of low-risk disease causes harm without benefit.
More than one path
For low-risk disease, active surveillance and definitive treatment are both NCCN-recommended. The choice depends on the patient's life situation, risk tolerance, and values — not just the biology.
Clear, structured communication
Every consult ends with a written summary of options, including the do-nothing-now option and the trade-offs each path carries.
Frequently Asked Questions
Should every man get a PSA test?
PSA screening is the most controversial test in oncology. Routine testing is not recommended for all men because it can detect indolent cancers that would never cause harm. Discussion is recommended for men 50 to 70, earlier if family history.
What is active surveillance?
Active surveillance is a real medical option for low-risk prostate cancer (Gleason 6, contained). PSA every 6 months, MRI every year, biopsy if anything changes. Treatment is offered only if the disease progresses. Many men live a normal life this way for a decade or more.
What does Gleason score mean?
Gleason grades how aggressive prostate cancer cells look. Total ranges from 6 (least aggressive) to 10 (most aggressive). Gleason 6 is low-risk and often suitable for active surveillance. Gleason 7 is intermediate-risk. Gleason 8-10 typically warrants prompt treatment.
Should I get a second opinion?
Yes, especially for newly diagnosed low-risk disease. The choice between active surveillance and definitive treatment is the textbook example of more-than-one-right-answer in oncology.
What treatments are available for advanced prostate cancer?
Hormonal therapy (androgen deprivation), often combined with chemotherapy or newer hormonal agents. Targeted therapy with PARP inhibitors for BRCA mutations. Immunotherapy in select cases.
Consult Dr. Madhav Danthala
For first opinion, second opinion, or treatment planning: